Who to call at Summit Therapeutics Inc., and when
Fundz watches for the moments Summit Therapeutics Inc. starts buying, and tells you who to reach.
- An alert the day Summit Therapeutics Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Summit Therapeutics Inc., from your own LinkedIn network
Summit Therapeutics Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
www.smmttx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Summit Therapeutics Inc. raised $2.0 billion in gross proceeds through a private placement of Class A Convertible Preferred Stock with AstraZeneca Holdings B.V. on September 28, 2026. This substantial capital influx significantly strengthens the company's financial position for growth and strategic initiatives.
Key Takeaways
Summit issued 108,955.3686 shares of newly designated Class A Convertible Preferred Stock at $18,356.14 per share to AstraZeneca
Each preferred share is convertible into 1,000 shares of common stock at $0.01 par value, providing conversion optionality
2 more takeaways
Related Filings (4)
4 more filings from Summit Therapeutics Inc. in the last 90 days
Filing Overview
What This Means
Summit Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.